Corcept Therapeutics (CORT) Expected to Announce Quarterly Earnings on Thursday

Corcept Therapeutics (NASDAQ:CORT) will likely be issuing its quarterly earnings data after the market closes on Thursday, February 20th. Analysts expect the company to announce earnings of $0.37 per share and revenue of $200.12 million for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Corcept Therapeutics Stock Performance

Shares of CORT stock opened at $72.72 on Tuesday. The firm’s 50 day moving average price is $58.24 and its 200-day moving average price is $49.72. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. Corcept Therapeutics has a one year low of $20.84 and a one year high of $74.61. The firm has a market cap of $7.62 billion, a P/E ratio of 57.71 and a beta of 0.58.

Insider Transactions at Corcept Therapeutics

In related news, insider Sean Maduck sold 20,000 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total value of $1,007,800.00. Following the sale, the insider now directly owns 85,318 shares of the company’s stock, valued at $4,299,174.02. This represents a 18.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $68.08, for a total transaction of $149,776.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,011 shares of company stock valued at $1,479,608. Corporate insiders own 20.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on CORT. Canaccord Genuity Group increased their target price on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, January 30th. StockNews.com lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Corcept Therapeutics in a report on Friday, February 7th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $88.25.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.